

**Client**  
**Gurugram**  
 Pathkind Diagnostics Pvt. Ltd.  
 Plot No. 55-56, Udhog Vihar Ph-IV, Gurugram - 122015

**Processed By**  
 Pathkind Diagnostics Pvt. Ltd.  
 Plot No. 55-56, Udhog Vihar Ph-IV, Gurugram - 122015

<b>Name</b> : Mr. FC19	<b>Billing Date</b> : 07/07/2023 12:23:21
<b>Age</b> : 35 Yrs	<b>Sample Collected on</b> : 10/07/2023 10:01:31
<b>Sex</b> : Male	<b>Sample Received on</b> : 10/07/2023 11:02:13
<b>P. ID No.</b> : P1000100012761	<b>Report Released on</b> : 18/07/2023 17:34:38
<b>Accession No</b> : 10002304817	<b>Barcode No.</b> : 10002304817-01
<b>Referring Doctor</b> : Self	<b>Ref no.</b> :
<b>Referred By</b> :	

**Report Status - Final**

Test Name	Result	Biological Ref. Interval	Unit
-----------	--------	--------------------------	------

**HAEMATOLOGY**

**Leukemia Lymphoma Comprehensive Diagnosis Panel**

Sample: Sodium Heparin

**Immunophenotyping findings:** Flowcytometric immunophenotyping of Peripheral blood sample shows ~50% Blast population which are CD13+ , CD33+, cyMPO+, CD117+ , CD34+ and~ 30% Monocytes population which are cyMPO+, CD14+, CD34+, CD13+, CD33+, and CD64+ and negative for both cy79a, CD10, CD20, cyCD3, CD19, HLA-DR, CD38, and CD7

**Impression:** Acute Myeloid Leukemia With Monocytic Diffrentiation.

**Advice:** Cytogenetics and Molecular Studies.

**Markers used:** CD45, cyCD79a, cyCD3,CD10, CD20, CD7, HLA- DR, CD38, CD19, CD34, CD13, CD14, CD33, CD64, CD117, cyMPO.

Marker	Blast	Monocytes
CD7	Negative	Negative
CD38	Negative	Negative
CD19	Negative	Negative
cyMPO	<b>Positive</b>	<b>Positive</b>
CD13	<b>Positive</b>	<b>Positive</b>
Cy79a	Negative	Negative
CD14	Negative	<b>Positive</b>

10002304817 Mr. FC19



**Client**  
**Gurugram**  
Pathkind Diagnostics Pvt. Ltd.  
Plot No. 55-56, Udhog Vihar Ph-IV, Gurugram - 122015

**Processed By**  
**Pathkind Diagnostics Pvt. Ltd.**  
Plot No. 55-56, Udhog Vihar Ph-IV, Gurugram - 122015

<b>Name</b> : Mr. FC19	<b>Billing Date</b> : 07/07/2023 12:23:21
<b>Age</b> : 35 Yrs	<b>Sample Collected on</b> : 10/07/2023 10:01:31
<b>Sex</b> : Male	<b>Sample Received on</b> : 10/07/2023 11:02:13
<b>P. ID No.</b> : P1000100012761	<b>Report Released on</b> : 18/07/2023 17:34:38
<b>Accession No</b> : 10002304817	<b>Barcode No.</b> : 10002304817-01
<b>Referring Doctor</b> : Self	
<b>Referred By</b> :	<b>Ref no.</b> :

**Report Status - Final**

Test Name	Result	Biological Ref. Interval	Unit
CyCD3	Negative	Negative	
CD10	Negative	Negative	
CD20	Negative	Negative	
HLA-DR	Negative	Negative	
CD33	<b>Positive</b>	<b>Positive</b>	
CD117	<b>Positive</b>	Negative	
CD64	Negative	<b>Positive</b>	
CD34	<b>Positive</b>	<b>Positive</b>	
CD45	<b>Positive</b>	<b>Positive</b>	

**Comment:** The samples was run on BC Navios 10 color flow cytometer as per the standardized international protocol. FSC vs SSC was used to gate viable cells. CD45vs SSC gating strategy is used. Software used for analysis is Kaluza 2.1.3

Note: Investigation should be interpreted understanding the limitation of the sample quality and various statistical parameters. An isolated laboratory report never forms a basis of any treatment decision. It should always be interpreted with the clinical course by the primary

\*\* End of Report\*\*




**Dr. Aarti Khanna Nagpal**  
DNB (Pathology)  
Senior Consultant




Patient Name- DUMMY

BARCODE:-


[Viable] CD45 APCH7 / SS INT




[All Population] CyCD79a PE / Cy MPO FITC




[All Population] CD34 PECF594 / CD14 PC5



[All Population] CD33 PC7 / CD13 PE



[All Population] CD64 FITC / CD117 PC5



[All Population] HLA DR PB / CD34 PECF594

